Europese Unie - Nederlands - EMA (European Medicines Agency)

albireo - odevixibat - cholestasis, intrahepatic - gal en levertherapie - bylvay is indicated for the treatment of progressive familial intrahepatic cholestasis (pfic) in patients aged 6 months or older (see sections 4. 4 en 5.